ArticleAnalytical and bioanalytical chemistry2026
Fluorescence polarization enzyme assay: a novel approach for the quantification of quercetin based on its interaction with α-amylase.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disease Biomarker Detection Using Fluorescence Polarization Assays: Principles and Clinical Applications.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Traditional fluorescence polarization immunoassay (FPIA) requires costly monoclonal antibodies. This work develops a cost-effective fluorescence polarization enzyme assay (FPEA) for quercetin, employing α-amylase as a significantly cheaper recognition agent. Based on competitive binding with a fluorescent zearalenone tracer, the assay achieves a detection limit of 1.7 mg/mL, a working range of 2.3-6.4 mg/mL, and completes analysis within 5 min, offering a substantial time saving versus typical HPLC runs (~ 20 min). It demonstrates high specificity, with only minimal cross-reactivity to rutin (0.1%) and none to dihydroquercetin, gallic acid, and acarbose. FPEA analysis yielded a quercetin*α-amylase binding affinity constant of 3.9 × 10
Indexed as
Identifiers
42017969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.